Skip to content

An fMRI investigation of Pavlovian Instrumental Transfer and Avoidance Learning with Primary Reinforcement in Psychopathy

An fMRI investigation of Pavlovian Instrumental Transfer and Avoidance Learning with Primary Reinforcement in Psychopathy - An fMRI study of PIT in psychopathy.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON32649
Enrollment
80
Registered
2010-01-07
Start date
2010-05-02
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychopathy sociopathy

Interventions

None listed

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age 18-55 years. • Men. • Group 1: Patient, meeting the DSM-IV criteria for ASPD and scoring * 26 on the PCL-R. • Group 2: Patient, meeting the DSM-IV criteria for ASPD; and showing low levels of psychopathy (PCL-R

Exclusion criteria

Exclusion criteria: General exclusion criteria for fMRI: Metal implants or splinters, surgical clips, protheses, artificial heart valves, claustrophobia, electronic equipment in body (such as a pacemaker), pregnancy, epilepsy. ;Psychiatric: • Recurrent Major Depressive disorder or Single Major Depressive disorder within five years. • Bipolar disorder • Schizophrenia, delusional disorder, schizoaffective disorder, schizopheniform disorder or other psychotic disorders • Schizoid or schizotypical personality disorder • (Current) alcohol- or substance intoxication • Anti-social personality disorder/Psychopathy co-morbidity in healthy volunteers • ADHD • First degree relatives with DSM IV axis I schizophrenia, or schizophreniform disorder • Mental retardation;Somatic • Visual and auditory disorders • Neurological disorders • First degree relatives with any relevant neurological disorders;Pre-testing use of drugs and substances • Use of alcohol within 24 hours before measurement. • Use of cannabis or other illicit drugs within the week before measurement. • Use of any psychotropic medication, other than benzodiazepines, during the 5 days before measurement. • Use of benzodiazepines within 3 times T¬1/2 before measurement. • Smoking within 3 hours before measurement.

Design outcomes

Primary

MeasureTime frame
During the performance of the tasks we will collect behavioural, psychophysiological (heart rate and eye tracking) data and functional imaging data.

Secondary

MeasureTime frame
-

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)